Wednesday, February 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Powdered Measles Vaccine Found Safe in Early Trials

by Global Biodefense Staff
November 26, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to research published this week in the journal Vaccine.

In 2013, measles killed 145,700 people, most of them children, according to the World Health Organization. That’s despite the fact that the conventional injectable vaccine against the measles virus is effective.

“Delivering vaccines in the conventional way, with needle injections, poses some serious challenges, especially in resource-poor parts of the world,” said Robert Sievers, co-author of the new paper, a fellow of the Cooperative Institute for Research in Environmental Sciences (CIRES) and also a professor in the University of Colorado Boulder’s Department of Chemistry and Biochemistry.

His team innovated a dry delivery technique for the measles vaccine to eliminate the need for injections, liquid storage, and other challenges, such as vaccine contamination. “You don’t need to worry about needles; you don’t need to worry about reconstituting vaccines with clean water; you don’t need to worry about disposal of sharps waste or other vaccine wastage issues; and dry delivery is cheaper,” Sievers said.

The new paper represents the first successful Phase I clinical trial for a dry powder vaccine, he said. Sievers and his co-authors identified no adverse effects of the powdered and inhaled vaccine when tested in 60 healthy men who were already immune to measles. In this safety-focused clinical trial, they tested delivery with two devices–the Aktiv-Dry PuffHaler and BD Technologies Solovent–compared with the usual under-the-skin liquid injection method.

“Out of an abundance of caution, we test first in people who have already had the disease, or been injected earlier by needles with liquid vaccines,” he explained. The men in all three groups responded similarly, with no clinically relevant side effects and some evidence of a positive immune response to vaccination. Because the men were already immune to the disease, this experiment could not yet compare effectiveness of the vaccines, measured by immune response. That will be the primary goal of follow-on Phase II/III pivotal trials.

“It is very good news that we encountered no problems, and now we can move on,” Sievers said. The next phase of tests could include work in people who are not yet immune to measles, including women and children.

Tags: MeaslesThermostability

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC